Nasdaq FDA - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

FDA approves Vertex's first-in-class non-opioid analgesic for acute pain

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid analgesic,

Hosted on MSN · 2h

Vertex gets FDA approval for non-opioid pain reliever

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) rose 3% in post-market trading Thursday on news the company had received FDA approval for its non-opioid pain reliever Journavx, also known as suzetrigine.

Wall Street Journal · 2h

First New Non-Opioid Painkiller in Decades Gets FDA Approval

Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive alternative to notorious drugs like OxyContin.

Axsome, FDA and migraine

Hosted on MSN · 4h

Axsome gets FDA approval for Symbravo for migraine

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,

Reuters on MSN · 2h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.

Business Insider · 5h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

3hon MSN

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

GlobalData on MSN8h

Beta Bionics raises $204m to kickstart medtech IPO season

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its anticipated target. The US-based company sold 12 million shares of its common ...

2hon MSN

Clene Inc. secures additional NIH grant funds for ALS therapy

Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...

3don MSN

Atara to cut 50% of workforce amid FDA woes

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo. The ...

10 Best ASX Stocks to Buy According to Hedge Funds

According to a report by the Australian Bureau of Statistics (ABS) published on December 4, 2024, the Australian economy grew ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results